Biohm gets $7.5 million investment from private equity funds

By Hank Schultz

- Last updated on GMT

©Getty Images - rapid eye
©Getty Images - rapid eye

Related tags Investment Finance mycobiome

Supplement manufacturer Biohm Health has announced a $7.5 million cash infusion that the company says will help it to further develop the use of artificial intelligence in its product formulations.

The company was founded on the science relating to the importance of the fungal components of the gut microbiome.  That followed from an influential paper published by one of the cofounders, Mahmoud Ghannoum, PhD, a professor at Case Western Reserve University in Cleveland, OH. His research focused on the interaction of the fungal and microbial components that contribute to gut dysbiosis.  His son, Afif Ghannoum, the other cofounder who serves as the company’s CEO, says his father coined the term ‘mycobiome’ and his work has been cited more than 16,000 times.

Balance in the gut

The company’s first product was a probiotic blend that purported to balance the fungal and microbial aspects of the human gut.  Branded as Biohm Probiotic Blend or Biohm 15B depending on the dosage, the product is a proprietary blend of B. breve, L. rhamnosus, S. boulardi and L. acidophilus​ probiotic strains and a yeast strain.

More recent product additions included a Super Reds product, which includes the probiotic blend along with beet root powder, pomegranate and açai and other polyphenol rich sources, and Super Greens product that incorporates Spirulina and Chlorella algae.

“The Super Greens has been around for a couple of years now and is our No. 1 seller.  The Super Reds has climbed to be our second most popular product,”​ Afif Ghannoum said.

Broad base of investors

A number of private equity funds subscribed to the new capital raise. They include Middleland Capital’s VTC Ventures, which led the effort, along wit with additional investments from Felton Group, LLC, Jobs Ohio Growth Capital Fund, Aztec Capital Management LLC, Cleveland Life Science Advisors, Valley Growth Ventures, LLC, Jump Start, Inc. and other investors.

“While we are pushing the category in microbiome research and applied science, this raise allows us to level up to a new stratum of technology which equates to a significant ‘needle move’ on microbiome optimization,”​ noted Afif Ghannoum. “As we well know now, gut health is at the center of wellness. We are thrilled about the broad scale impact this raise could have on personalized health.”

Related news

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Custom Biotic Solutions for Digestive Health

Custom Biotic Solutions for Digestive Health

Content provided by ADM: Innovation that Feeds the Future | 10-Oct-2023 | White Paper

A growing body of evidence shows gut health can affect digestive health, well-being, and many health areas in between.

Related suppliers

Follow us


View more